Kenneth Foreman, founder of Ars Exemplar, has nearly 20 years experience in the pharmaceutical industry, working on programs which have led to several INDs in diverse therapeutic areas. Convinced that the industry is looking for viable outsourcing opportunities in computational chemistry, he established Ars Exemplar in late 2015. Ars Exemplar can provide support for most modeling aspects of drug discovery, including
– Target vetting
– Protein modeling
– Diversity analysis in compound selection for screening
– Analysis of high throughput screens
– Structure and ligand based virtual screens
– Binding hypothesis generation
– Compound property optimization, including for affinity and ADMET
– Quantum chemical calculations
– Simulations
– Publication quality images
Although most interactions are expected with industry, collaborations with academic labs are supported at a discounted rate.
Recent Publications:
– A General Model for Predicting the Binding Affinity of Reversibly and Irreversibly Linked Dimers. DOI: 10.1371/journal.pone.0188134
– Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in Myc over-expressing cancer cell lines. DOI: 10.1371/journal.pone.0121793.eCollection 2015
– C-terminal Domain of SMYD3 Serves as a Unique HSP90-Regulated Motif in Oncogenesis. DOI: 10.18632/oncotarget.2970